Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-014",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "claude-sonnet-4",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"Blood-Brain Barrier SPM Shuttle System\",\n      \"description\": \"Engineered transferrin receptor-targeting nanocarriers loaded with stable SPM analogs could bypass the blood-brain barrier's exclusion of endogenous resolvins. This shuttle system would deliver therapeutic concentrations of pro-resolving mediators directly to neuroinflammatory foci.\",\n      \"target_gene\": \"TFRC\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.8,\n        \"evidence_strength\": 0.7,\n        \"novelty\": 0.6,\n        \"feasibility\": 0.9,\n        \"therapeutic_potential\": 0.8,\n        \"druggability\": 0.9,\n        \"safety_profile\": 0.8,\n        \"competitive_landscape\": 0.7,\n        \"data_availability\": 0.8,\n        \"reproducibility\": 0.8\n      },\n      \"composite_score\": 0.78\n    },\n    {\n      \"title\": \"Senescent Microglia Resolution via Maresins-Senolytics Combination\",\n      \"description\": \"Combined treatment with maresin analogs plus selective senolytic agents could eliminate senescent microglia while simultaneously activating resolution programs in remaining cells. This dual approach would clear inflammatory 'zombie' cells while restoring healthy microglial function.\",\n      \"target_gene\": \"BCL2L1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.7,\n        \"evidence_strength\": 0.6,\n        \"novelty\": 0.8,\n        \"feasibility\": 0.7,\n        \"therapeutic_potential\": 0.8,\n        \"druggability\": 0.8,\n        \"safety_profile\": 0.6,\n        \"competitive_landscape\": 0.8,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.7\n      },\n      \"composite_score\": 0.72\n    },\n    {\n      \"title\": \"Microglial Efferocytosis Enhancement via GPR32 Superagonists\",\n      \"description\": \"Synthetic super-agonists of GPR32 (RvD1 receptor) could restore microglial phagocytic capacity for clearing protein aggregates and apoptotic neurons. Enhanced efferocytosis would break the cycle of failed clearance that perpetuates chronic neuroinflammation in neurodegeneration.\",\n      \"target_gene\": \"CMKLR1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.6,\n        \"evidence_strength\": 0.5,\n        \"novelty\": 0.7,\n        \"feasibility\": 0.6,\n        \"therapeutic_potential\": 0.7,\n        \"druggability\": 0.7,\n        \"safety_profile\": 0.5,\n        \"competitive_landscape\": 0.9,\n        \"data_availability\": 0.6,\n        \"reproducibility\": 0.6\n      },\n      \"composite_score\": 0.64\n    },\n    {\n      \"title\": \"Circadian-Gated Maresin Biosynthesis Amplification\",\n      \"description\": \"Chronotherapeutic activation of maresin biosynthesis during natural resolution phases (early morning) could restore circadian inflammation resolution. Time-restricted delivery of MaR1 precursors or ALOX12 activators would work with endogenous circadian machinery to enhance resolution efficiency.\",\n      \"target_gene\": \"ALOX12\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.5,\n        \"evidence_strength\": 0.4,\n        \"novelty\": 0.8,\n        \"feasibility\": 0.6,\n        \"therapeutic_potential\": 0.6,\n        \"druggability\": 0.6,\n        \"safety_profile\": 0.7,\n        \"competitive_landscape\": 0.9,\n        \"data_availability\": 0.5,\n        \"reproducibility\": 0.5\n      },\n      \"composite_score\": 0.61\n    },\n    {\n      \"title\": \"Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution\",\n      \"description\": \"Cell-penetrating peptide mimetics of NPD1/PD1 could specifically target oligodendrocytes to resolve myelin-associated inflammation. These mimetics would activate the oligodendrocyte resolution program, promoting myelin repair while suppressing microglia-mediated demyelination.\",\n      \"target_gene\": \"GPR37\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.4,\n        \"evidence_strength\": 0.3,\n        \"novelty\": 0.8,\n        \"feasibility\": 0.5,\n        \"therapeutic_potential\": 0.7,\n        \"druggability\": 0.5,\n        \"safety_profile\": 0.6,\n        \"competitive_landscape\": 0.9,\n        \"data_availability\": 0.4,\n        \"reproducibility\": 0.4\n      },\n      \"composite_score\": 0.55\n    },\n    {\n      \"title\": \"Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy\",\n      \"description\": \"Viral-mediated delivery of ALOX15 specifically to reactive astrocytes could restore endogenous LXA4 biosynthesis. This would reactivate the astrocytic resolution program, converting neurotoxic A1 astrocytes back to neuroprotective phenotypes while preserving blood-brain barrier integrity.\",\n      \"target_gene\": \"ALOX15\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.5,\n        \"evidence_strength\": 0.4,\n        \"novelty\": 0.7,\n        \"feasibility\": 0.4,\n        \"therapeutic_potential\": 0.7,\n        \"druggability\": 0.8,\n        \"safety_profile\": 0.5,\n        \"competitive_landscape\": 0.8,\n        \"data_availability\": 0.5,\n        \"reproducibility\": 0.4\n      },\n      \"composite_score\": 0.54\n    },\n    {\n      \"title\": \"Mitochondrial SPM Synthesis Platform Engineering\",\n      \"description\": \"Engineered mitochondria containing optimized SPM biosynthetic machinery could be delivered to microglia via nanoparticles. These 'resolvin factories' would provide sustained local production of pro-resolving mediators at sites of neuroinflammation, bypassing systemic limitations.\",\n      \"target_gene\": \"ALOX5\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.2,\n        \"evidence_strength\": 0.2,\n        \"novelty\": 0.9,\n        \"feasibility\": 0.1,\n        \"therapeutic_potential\": 0.6,\n        \"druggability\": 0.2,\n        \"safety_profile\": 0.3,\n        \"competitive_landscape\": 1.0,\n        \"data_availability\": 0.2,\n        \"reproducibility\": 0.2\n      },\n      \"composite_score\": 0.33\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"TFRC\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"transferrin_receptor\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"transferrin_receptor\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"blood_brain_barrier_transport\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"mediates\"\n    },\n    {\n      \"source_id\": \"CMKLR1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"GPR32\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"GPR32\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"microglial_efferocytosis\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"microglial_efferocytosis\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"neuroinflammation\",\n      \"target_type\": \"disease\",\n      \"relation\": \"resolves\"\n    },\n    {\n      \"source_id\": \"BCL2L1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"BCL-xL\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"BCL-xL\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"senescent_cell_survival\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"promotes\"\n    },\n    {\n      \"source_id\": \"ALOX12\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"12-lipoxygenase\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"12-lipoxygenase\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"maresin_biosynthesis\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"catalyzes\"\n    },\n    {\n      \"source_id\": \"ALOX15\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"15-lipoxygenase\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"15-lipoxygenase\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"lipoxin_A4_synthesis\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"catalyzes\"\n    },\n    {\n      \"source_id\": \"lipoxin_A4_synthesis\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"astrocyte_polarization\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"GPR37\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"GPR37_receptor\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"GPR37_receptor\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"oligodendrocyte_survival\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"mediates\"\n    }\n  ],\n  \"synthesis_summary\": \"The synthesis reveals a clear ranking favoring approaches with established technological platforms and manageable risk profiles. The Blood-Brain Barrier SPM Shuttle System emerges as the top candidate (score: 0.78) due to its combination of strong mechanistic rationale, proven transferrin receptor-targeting technology, and clear regulatory pathway. The approach leverages existing BBB shuttle platforms from companies like Genentech while addressing the fundamental challenge of delivering specialized pro-resolving mediators to neuroinflammatory sites. The Senescent Microglia Resolution combination therapy ranks second (score: 0.72), benefiting from existing clinical-stage senolytic compounds and a novel but mechanistically sound combination rationale.\\n\\nThe lower-ranked hypotheses suffer from significant technical or safety challenges that outweigh their innovative potential. The GPR32 superagonist approach faces blood-brain barrier penetration hurdles and safety concerns about chronic receptor activation. The gene therapy and mitochondrial engineering approaches, while scientifically intriguing, present prohibitive technical complexity and regulatory challenges for near-term development. The knowledge graph analysis reveals critical pathway connections, particularly highlighting how transferrin receptor-mediated transport connects to neuroinflammation resolution, and how multiple lipoxygenase enzymes converge on specialized pro-resolving mediator synthesis. The top-tier approaches should proceed with strategic partnerships to leverage existing platforms, while lower-tier concepts merit academic collaboration for foundational validation before commercial consideration.\"\n}\n```",
  "tokens_used": "2514"
}